Trial Information
FDG-PET-Stratified R-DICEP and R-BEAM/ASCT For Diffuse Large B-Cell Lymphoma
Inclusion Criteria:
- Age 18-65 years
- Diagnosis of Diffuse Large B-Cell Lymphoma
- Adverse Prognosis = Stage 3 or 4 and elevated LDH
- No more than one prior cycle of R-CHOP chemotherapy
- Adequate cardiac function
- No central nervous system involvement by lymphoma
Exclusion Criteria:
- Histological diagnosis other than Diffuse Large B-cell Lymphoma
- Pregnant or lactating females
- Use of other anti-cancer therapies
- Other serious illness that would compromise study participation
- Prior malignancy
- Prior stem cell transplant or radiotherapy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Douglas Stewart, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Alberta Health Services
Authority:
Canada: Health Canada
Study ID:
0307003
NCT ID:
NCT00530179
Start Date:
July 2007
Completion Date:
Related Keywords:
- Diffuse Large B Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
- Positron Emission Tomography
- CHOP Chemotherapy protocol
- Stem Cell Transplantation
- Fluorodeoxyglucose F18
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse